Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05389267 · ClinicalTrials.gov registry record · Phase 1
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
A Phase 1 study of Glaucoma and Ocular Hypertension, sponsored by Laboratoires Thea.
- Active
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05389267: Active Phase 1 study of Glaucoma and Ocular Hypertension, sponsored by Laboratoires Thea.
NCT05389267 is a Phase 1 study of Glaucoma and Ocular Hypertension that is active but no longer recruiting, run by Laboratoires Thea. The registered enrollment target is 120 participants, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05389267, a Phase 1 study of Glaucoma and Ocular Hypertension, is active but no longer recruiting, sponsored by Laboratoires Thea.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The study purpose is to evaluate the safety of T4090.
Primary Outcome
Ocular and systemic treatment-emergent adverse events, serious TEAE, IMP-related TEAE, TEAE leading to premature IMP discontinuation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Kinezodianone R hydrochloride
Study Locations (1)
California
- Dr EL-HARAZI - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 1 |
What the registry record for NCT05389267 still lists
NCT05389267 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05389267 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05389267 about?
NCT05389267 is a clinical study titled "Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.". The study purpose is to evaluate the safety of T4090.
What is the current status of trial NCT05389267?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2022-07-05. Estimated completion is 2024-12-31.
What conditions does trial NCT05389267 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension.
What interventions are being tested in trial NCT05389267?
The interventions under investigation include: Placebo (DRUG), Kinezodianone R hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05389267?
This trial is sponsored by Laboratoires Thea, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05389267 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05389267's enrollment target sits among peer trials
120 38th of 92 higher than 55 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
-
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
COMPLETED · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
COMPLETED · Phase 1
-
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI